Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol‐5D response of biological treatment in psoriasis: 10 years of real‐world data in the Swedish National Psoriasis Register

Hjalte, Frida; Carlsson, Katarina Steen; Schmitt‐Egenolf, Marcus

doi:10.1111/bjd.15757

Cited by 14 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, short-term data on biologics are robust, with up to 70.7% of patients achieving more than 90% reduction in PASI and up to 89.7% achieving a PASI 75 response after 12 weeks of treatment dependent on the specific biologic and dose used (31). Regarding the longer-term effects of biologics, a Swedish study found that switching to biologics was associated with a sustained effect at 10 years with a PASI reduction of 82.8%, a DLQI improvement of 85.7%, and an EQ-5D improvement of 11.0% (32). A study conducted on patients with moderate-to-severe psoriasis comparing the effect of biologics with that of systemic, topical, or light treatment found that biologics resulted in an average mean reduction in DLQI of 6.6 at week 24 (33).…”

Section: Discussionmentioning

confidence: 99%

Effect of Dead Sea Climatotherapy on Psoriasis; A Prospective Cohort Study

et al. 2020

View full text Add to dashboard Cite

Background: Dead Sea climatotherapy (DSC) is a treatment option for psoriasis in Denmark. However, the response to DSC has not been particularly well studied. Aim: We sought to determine effectiveness and response duration of DSC on psoriasis-related outcome parameters. Methods: Eighteen patients participated in a 4-week treatment program in Ein Gedi in Israel. Treatment, consisting of sun exposure and bathing, was individualized. Results: DSC was associated with a mean 13.0-point reduction (88%) in Psoriasis Area and Severity Index and a mean reduction of 2.3 (76.7%) on the 5-point Investigator's Global Assessment Scale. Furthermore, patients' quality of life improved measured by the Dermatology Quality of Life Index and EuroQol 5D index values. The mean time from treatment end to reappearance of visible skin symptoms was 93.8 days (SD: 62.5, range: 31-219 days). Conclusions: Our results confirm that DSC has an immediate effect on skin manifestations and improves quality of life, but long-term disease control is not observed.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Dead Sea Climatotherapy on Psoriasis; A Prospective Cohort Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[28][29][30] However, data from the PsoReg registry showed that the median PASI score in bio-na€ ıve patients who switched to biologic therapy changed from 11.6 at baseline to 3 at threeto-five months after switching and this change persisted over the next six-to-nine years. 31 Another recent study showed that adding topical therapy to patients that have not achieved an adequate response with biologic therapies, may help achieve treat-to-target criteria. 32 In the absence of validated, hard biomarker endpoints, such as the haemoglobin-a1c goal in the treatment of diabetes, treatment targets in psoriatic disease are clinical activity goals that both clinicians and patients can use to evaluate treatment efficacy in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

The National Psoriasis Foundation psoriasis treatment targets in real‐world patients: prevalence and association with patient‐reported outcomes in the Corrona Psoriasis Registry

Merola

Pérez-Chada

Siegel

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Introduction The National Psoriasis Foundation (NPF) published treat‐to‐target guidelines for psoriasis, yet their applicability in clinical practice remains unknown. Objectives To estimate the proportion of psoriasis patients meeting the NPF's body surface area (BSA) ‘target’ (≤1%) and ‘acceptable’ (≤3%) response criteria and the cross‐sectional associations of these criteria with patient‐reported outcomes (PROs) in the Corrona Psoriasis Registry. Methods Separately for three independent cross‐sectional cohorts of patients at the (i) enrolment, (ii) 6‐month and (iii) 12‐month visits, we calculated the proportion of patients with BSA ≤1% and ≤3%. Furthermore, we calculated odds ratios estimating the risk of PROs associated with not meeting criteria in the 6‐month cohort. Results The enrolment, 6‐ and 12‐month cohorts included 2794, 1310 and 629 patients, respectively. At enrolment, 24% of patients had a BSA ≤ 1% and 41% a BSA ≤ 3%. In the 6‐month cohort, 43%/64% had a BSA ≤ 1%/BSA ≤ 3%. In the 12‐month cohort, 46%/69% of patients had a BSA ≤ 1%/BSA ≤ 3%. Patients not at target/acceptable criteria had higher odds for worse quality of life compared with those who were. Conclusion While most patients at 6‐ and 12‐month visits were at the ‘acceptable’ response, less than half were at the ‘target’ response despite systemic therapy. There remain unmet needs to optimize psoriasis therapy and further validate current treat‐to‐target guidelines.

show abstract

“…In this issue of the BJD Hjalte et al . report on their observational study of 583 patients from the Swedish National Psoriasis Register (PsoReg).…”

mentioning

confidence: 99%

“…report on their observational study of 583 patients from the Swedish National Psoriasis Register (PsoReg). Patients were followed for up to 9 years, making this one of the longest biological treatment follow‐up databases . Main clinical outcomes included a disease severity measure, Psoriasis Area and Severity Index (PASI), and two HRQoL measures, Dermatology Life Quality Index (DLQI) and EuroQol‐5D (EQ‐5D).…”

mentioning

confidence: 99%